GDA and breast cancer: GSEA results demonstrated that the MTORC1 signaling pathway is significantly predicted to be inhibited in non-lung metastatic ER(-) breast cancer tissues with low levels of Gαh expression (p<0.01) but activated in lung metastatic ER(-) breast cancer tissues with high levels of Gαh expression (Figure 1B).